AstraZeneca

April 15, 2015November 6, 2015

Practice Fusion And AstraZeneca Partner for PHM Initiative For Asthma, COPD

Asthma, News

Practice Fusion, an Electronic Health Records (EHR) provider, and AstraZeneca recently renounced a Population Health Management (PHM) program for members of Practice Fusion’s community that includes about 112,000 medical professionals. The program provides data-driven insights that ... Read more

March 23, 2015November 9, 2015

AstraZeneca Presents Positive Phase III Results for COPD Therapy

COPD, News

AstraZeneca recently presented encouraging data from its phase III PINNACLE program focused on evaluating PT003 as a potential treatment for chronic obstructive pulmonary disease (COPD). The program is comprised of two 24-week ... Read more

March 16, 2015November 9, 2015

COPD Foundation Creates COPD Patient Registry

COPD, News

The COPD Foundation recently announced the COPD360 program, an innovative initiative to boost research and promote new approaches for chronic obstructive pulmonary disease (COPD). AstraZeneca is sponsoring the program in their continued efforts to treat COPD, a type of inflammatory ... Read more

February 20, 2015November 6, 2015

US Court Invalidates Patent for AstraZeneca Asthma Drug

Asthma, News

A federal judge in the United States decided last Friday that AstraZeneca PLC‘s patent regarding its Pulmicort Repsules treatment to address asthma was invalid; the market is now open to a second, cheaper ... Read more

February 11, 2015November 9, 2015

AstraZeneca Acquires Rights To Actavis’ Branded COPD Portfolio in Canada and US

COPD, News

Actavis and AstraZeneca have recently announced signing a new agreement assuring that AstraZeneca will acquire the rights to Actavis’ respiratory portfolio in both Canada and the United States for an upfront payment worth $600 million upon completion, ... Read more

December 17, 2014November 6, 2015

Dynavax and AstraZeneca Partner to Advance Asthma Therapy Study

Asthma, News

Dynavax Technologies Corp and AstraZeneca AB have signed an amendment regarding the Research Collaboration and License Agreement they had previously established. The partnership stipulates that AstraZeneca will be responsible for the financial support of ... Read more

October 2, 2014November 11, 2015

Benralizumab Shows Marginal Benefit for COPD Exacerbations

COPD, News

For 10-20% of chronic obstructive pulmonary disease (COPD) patients, a certain type of specialized immune cells called eosinophils produce eosinophilic airway inflammation and lead to acute exacerbations of COPD. A ... Read more